Children with rhinovirus-induced severe early wheezing have an increased risk of developing asthma later in life. The exact molecular mechanisms for this association are still mostly unknown. To identify potential changes in the transcriptional and epigenetic regulation in rhinovirus-associated atopic or nonatopic asthma, we analyzed a cohort of 5-year-old children (n = 45) according to the virus etiology of the first severe wheezing episode at the mean age of 13 months and to 5-year asthma outcome. The development of atopic asthma in children with early rhinovirusinduced wheezing was associated with DNA methylation changes at several genomic sites in chromosomal regions previously linked to asthma. The strongest changes in atopic asthma were detected in the promoter region of SMAD3 gene at chr 15q22.33 and introns of DDO/METTL24 genes at 6q21. These changes were validated to be present also at the average age of 8 years.
immune responses) and genetic variations. [12] [13] [14] [15] [16] Despite progress in rhinovirus research, the exact molecular mechanisms for this association are still mostly unknown. 17 Furthermore, early predictive biomarkers are needed for the identification of the rhinovirusinfected children with an increased risk for developing asthma and enabling design of effective intervention strategies to prevent asthma. 11, 18 For these reasons, we examined epigenomic and transcriptomic changes in 5-year-old children associated with the virus etiology of their first wheezing episode and later asthma status.
| ME TH ODS
The detailed study protocols are described in the Data S1.
| Clinical study protocol
The study protocol was approved by the Ethics Committee of the Turku University Hospital and for the first 12 months was registered at ClinicalTrials.gov (NCT00731575). At study entry, standard procedures were carried out as previously described. 19 The inclusion criteria were age 3-23 months, delivery at ≥36 gestational weeks, first wheezing episode and a written informed consent from a guardian.
Selected children were recruited to regular follow-up visits. Children were diagnosed to have current asthma at the 4-year follow-up visit if they met one or more of the subsequent criteria during the preceding 12 months: doctor-diagnosed asthma, regular use of doctorprescribed corticosteroid asthma therapy, use of oral corticosteroids for asthma exacerbations, acute asthma attack relieved by repeated use of bronchodilator. 20 Current atopic asthma was defined as asthma with laboratory-verified sensitization (IgE antibodies >0.35 kU/L) at the 4-year follow-up visit. Nonatopic asthma was defined as asthma without these. The statistical analysis is described in Data S1. 
| Epigenome and transcriptome analysis

| Targeted pyrosequencing
The oligos were designed with Pyromark Software Assay Design 2.0.
Samples were prepared, and pyrosequencing was carried out with
Qiagen's Pyromark Q24 according to the manufacturer's instructions.
The data were analyzed with Pyromark Advanced Software.
Unpaired t test was used to calculate the statistical differences between study groups. See the Data S1 for more details.
| RESULTS
| Patient characteristics
Originally, 124 first-time wheezing children were enrolled of whom 77 (62%) children participated in the 4-year follow-up visit (Table S1 ). Of these, 48 most representative children were selected for the transcriptome and epigenome studies according to the virus etiology of their first severe wheezing episode, and their 5-year asthma outcome as follows: rhinovirus + asthma + (n = 16), rhinovirus + asthma À (n = 16), and rhinovirus À asthma À (n = 16).
Three study subjects from the latter group were excluded after quality analysis. Further details of patient characteristics are shown in Tables S2 and S3 . Interestingly, no differences in gene expression (fold change cut off AE1.4, FDR ≤0.05) were observed to be associated with either atopic or nonatopic asthma at the time of sampling, although for example SMAD3 gene was detected to be expressed in the blood of the study subjects.
| Targeted validation and stability of the DNA methylation changes
The CpG methylation changes associated with atopic asthma at the DDO/METTL24 intron (chr6:110720839-110720905) and SMAD3
promoter (chr15:67356631-67356721) with RRBS (Table 1) were confirmed with targeted pyrosequencing of the samples collected at the average age of 5 years ( Figure 1A, Figure S1 ). Importantly, analysis of the samples collected from the same children at the average age of 8 years revealed that the methylation changes associated with atopic asthma in these 2 regions were still present 3 years later (P ≤ 5.08E-04; Figure 1B ).
| DISCUSSION
We detected epigenetic changes in several genomic regions in children who had suffered early rhinovirus-induced wheezing, and which associated with later onset of asthma. Interestingly, among the strongest changes associated with atopic asthma was DNA HLA-G gene, 33 kb upstream from the differentially methylated region, is an asthma susceptibility gene, 40 and its expression is induced by allergens. 41 Several other differentially methylated sites were also in the proximity of genes, such as ELN 42 or CYTIP, 43, 44 previously linked to lung or immune cell functions, or viral infections, therefore having potential functional significance in the atopic asthma.
Among the strongest changes associated with nonatopic asthma was DNA methylation change linked to PTGDS gene. PTGDS F I G U R E 1 Validation and stability of the DNA methylation changes associated with atopic asthma. The strongest DNA methylation changes associated with atopic asthma (rhinovirus + atopic asthma + vs rhinovirus + atopic asthma À) were validated with targeted pyrosequencing (A) at the average age of 5 y and (B) at the average age of 8 y in samples collected from the same children. In addition, to outlier box plots, the distribution of DNA methylation levels of individual CpG sites within the indicated region for each individual is shown in the figure. In addition, median methylation differences and t test P-values are shown in the figure catalyzes synthesis of prostaglandin D2, which mediates development and symptoms of asthma by recruiting Th2 cells and inducing contraction of airways smooth muscle cells. 45, 46 Prostaglandin D2 enhances proinflammatory actions of macrophages and subsequent neutrophil activation. 47 Therefore, altered regulation of PTGDS may be important in the development of nonatopic asthma.
In conclusion, our results demonstrate that epigenetic changes associated with rhinovirus-induced early wheezing and asthma can be detected in peripheral blood. The strongest changes associated with atopic asthma were localized in the genomic regions previously associated with asthma 15, 16, 36 and importantly for SMAD3 promoter and in DDO/METTL24 gene were detected at the age of both 5 and 8 years. Although we did not detect significant changes in the transcriptomes at the time of measurement, it is possible that the regulation of the affected genes is altered, for example in response to antigen challenge. Alternatively, the DNA methylation changes detected in blood reflect functional changes present in other tissues, such as airways.
ACKNOWLEDGMENTS
We thank the Finnish Functional Genomics Centre (University of Turku, Abo Akademi University and Biocenter Finland) for the infrastructure support.
CONF LICTS OF INTEREST
The authors declare that they have no conflicts of interest.
O R C I D
R. J. Lund http://orcid.org/0000-0002-1068-5918
A. Leino http://orcid.org/0000-0002-2828-7483
T. Jartti http://orcid.org/0000-0003-2748-5362
